Selected data models

You must log in to select data models for download or further analysis.

13 Search results.
Relevance Rating New first Old first

Eligibility Liver Transplantation NCT01139203

- 6/30/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT01139203

Fondaparinux in Addition to Intermittent Pneumatic Compression in Abdominal Surgery Patients at VTE Risk - NCT00038961 - Eligibility Criteria

- 10/15/19 - 1 form, 6 itemgroups, 31 items, 1 language
Itemgroups: Administrative documentation, Inclusion Criteria, Exclusion Criteria - Bleeding risk, Exclusion Criteria - Study Procedures, Exclusion Criteria - Trial methodology, Exclusion Criteria - Miscellaneous
Study ID: 103414 Clinical Study ID: 103414 Study Title: A Multicenter, Randomized, Double-blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression (IPC) Versus IPC Used Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal surgery Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00038961 https://clinicaltrials.gov/ct2/show/NCT00038961 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Fondaparinux Sodium Trade Name: Fondaparinux Sodium Study Indication: Thrombosis This phase III placebo-controlled trial studies the efficacy and safety of Fondaparinux as an additional prevention measure of venous thromboembolic events (VTE) in patients above the age of 40 with intermediate or high VTE risk undergoing abdominal surgery. The study consists of a Screening Visit (Visit 0), the baseline visit on Day 1, the day of the surgery (Visit 1), the treatment period (denoted in its entirety as Visit 2) consisting of administration of Fondaparinux (2.5mg subcutaneously once daily) or placebo starting on Day 1 and continuing at least up to Day 5, possibly up to Day 9, in parallel to intermittent pneumatic compression and possibly elastic stockings, followed by a mandatory bilateral venography no longer than 24 hours after study drug cessation, and finally a Follow-up Visit (Visit 3) on Day 30 +/- 2. This form contains the study's Eligbility Criteria, which are checked at Visit 1 (on Day 1, the day of the surgery).

Eligibility Of Bypass Graft of the Extremities NCT02492854

- 6/2/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Standard Versus PICO Dressings in Lower-Extremity Bypass Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02492854

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling NCT00937833 - Eligibility

- 4/17/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The purpose of this study is to determine the impact of an absorbable urethrovesical sling on the post-operative return of urinary continence after robot-assisted radical prostatectomy. ODM derived from: https://clinicaltrials.gov/show/NCT00937833

Subcutaneous fondaparinux sodium for prevention of venous thromboembolic events; Study ID: 104619 - Visit 01

- 10/22/18 - 1 form, 9 itemgroups, 69 items, 1 language
Itemgroups: Operative Surgical Procedures; Details, Hematology finding, Inclusion, Exclusion Criteria, Inclusion, Exclusion Criteria, Therapeutic procedure, Assignment, Exclusion Criteria, Therapeutic Procedures, Assignment
Study ID: 104619 Clinical Study ID: 63129 Study Title:A multinational, randomized, double-blind comparison of once daily subcutaneous fondaparinux sodium with placebo for the prevention of venous thromboembolic events in acutely ill medical patients (ARTEMIS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fondaparinux sodium Trade Name: Arixtra Study Indication: Thrombosis, Venous

Eligibility Eversion in Dermatologic Surgery NCT01770002

- 9/22/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?; ODM derived from: https://clinicaltrials.gov/show/NCT01770002 Sponsor: University of California, Davis Information provided by (Responsible Party): University of California, Davis Principal Investigator: Daniel Eisen, M.D. University of California, Davis

Eligibility Major Surgery NCT00655980

- 6/13/18 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Vitamins in Nitrous Oxide Study; ODM derived from: https://clinicaltrials.gov/show/NCT00655980

Eligibility Kidney Transplant NCT00659620

- 5/12/18 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy; ODM derived from: https://clinicaltrials.gov/show/NCT00659620

Eligibility Wound Therapy After Surgery NCT01611207 DRKS ID 00003498

- 7/4/17 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Dr. Marcus Redaèlli, Administative and scientific head of staffed offices of Interdisciplinary Centre for Health Services Research, University of Witten/Herdecke ClinicalTrials.gov Identifier: NCT01611207 History of Changes Other Study ID Numbers: 03-2012 DRKS ID 00003498 ( Registry Identifier: German Clinical Trials Register ) Study First Received: March 28, 2012 Last Updated: May 17, 2013 Evaluate the Efficacy of the Treatment of Iatrogenic Subcutaneous Abdominal Wounds (ISAW) After Surgery by Application of Negative Pressure Wound Therapy (NPWT) in Comparison to Standard Conventional Wound Therapy (SCWT) of the Clinical Routine (ISAW) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT01611207

Eligibility Cholecystectomy NCT01685775 DRKS00000341 DRKS00000341 - Eligibility Cholecystectomy NCT01685775 DRKS00000341

- 6/27/17 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Dirk R. Bulian, Principal Investigator, University of Witten/Herdecke ClinicalTrials.gov Identifier: NCT01685775 History of Changes Other Study ID Numbers: U1111-1114-7386 DRKS00000341 ( Registry Identifier: DRKS-ID ) Study First Received: September 4, 2012 Last Updated: October 12, 2013 Needlescopic Versus Transvaginal/Transumbilical Cholecystectomy (NATCH) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT01685775

Eligibility Adolescents with Extreme Obesity DRKS00004195 NCT02062164 DRKS00004172 - Eligibility Adolescents with Extreme Obesity NCT02062164 DRKS00004172

- 6/21/17 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Prof. Dr. Martin Wabitsch, Division Chief Pediatric Endocrinology and Diabetology, University of Ulm ClinicalTrials.gov Identifier: NCT02062164 History of Changes Other Study ID Numbers: U1111-1131-4384c DRKS00004172 ( Registry Identifier: Deutsches Register Klinischer Studien ) 01GI1120A ( Other Grant/Funding Number: German Ministry for Education and Research (BMBF) ) U1111-1131-8145 ( Other Identifier: UTN of overall project ) Study First Received: October 22, 2013 Last Updated: March 9, 2017 Weight Loss Surgery in Adolescents With Extreme Obesity (YES) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT02062164

Eligibility Kidney Transplant NCT00296296

- 4/12/17 - 1 form, 3 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Inclusion Criteria, Exclusion Criteria
Immunosuppression Impact on the Metabolic Control of First Kidney Transplant Recipients With Pre-Existing Type 2 Diabetes (DM); ODM derived from: https://clinicaltrials.gov/show/NCT00296296

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial